Navigation Links
Shingles Pain Treatment Will Benefit More Patients

LONDON, August 21 /PRNewswire/ -- The medicated pain relief plaster, (Versatis) is now approved by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for patients suffering pain following shingles(1) This reversal of the previous SMC decision (issued in February 2007) for Versatis (5% lidocaine medicated plaster) is based on significant new clinical and cost-effectiveness comparative data and brings prescribing availability of the treatment in line with England and Wales. These new data on Versatis will be presented for the first time at the International Association for the Study of Pain (IASP) Congress in Glasgow (17-22 August 2008).

The pain that persists for more than three months after the onset of the shingles rash is called Post-herpetic Neuralgia (PHN) (2). PHN affects approximately 200,000 people in the UK(3). PHN can be described as an incessant burning, stabbing or shooting pain. The pain can start several weeks or even months after the shingles rash has gone and can continue for weeks, months or years(4).

Licensed in the UK in 2007, Versatis offers sustained pain relief associated with PHN(5). Versatis is an innovative combination of local analgesic lidocaine and a soft hydrogel plaster. Application of the plaster to the skin releases an appropriate level of lidocaine into the skin to impair the transfer of signals which would be associated with the perception of pain.

Based on clinical trial data, Versatis is used as a continuous once-daily 12 hours on/12 hours off application schedule for 2-4 weeks and provides rapid and continuous pain relief from 30 minutes after application(6).

Dr Michael Serpell, Consultant and Senior Lecturer in Anaesthesia, Glasgow says: "The new recommendation from the SMC is to be welcomed. New data supporting the role of Versatis in post-herpetic neuralgia will further establish that such a novel, non-systemic treatment approach offers significant benefits in the older patient group who suffer co-morbidities and consequential polypharmacy".

Heather Wallace, Chairman of Pain Concern commented: "The SMC is to be congratulated on its revised decision for Versatis. They've taken a huge step forward in extending options for pain relief for people living with neuropathic pain. This decision will alleviate a lot of suffering".

The risk of developing PHN increases with age - it is most common in people aged over 50. About half of shingles cases affecting people of the age of 65 will cause PHN(7,8).

Prescribing Information

Versatis 5% medicated plaster. Refer to the Summary of Product Characteristics (SPC) for full details on side effects, warnings and contra-indications before prescribing. Presentation: Versatis is a medicated plaster (10cm x 14cm) containing 700 mg (5% w/w) of lidocaine in an aqueous adhesive base. Indication: Treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). Dosage and method of administration: Adults and elderly patients: Use up to three plasters for up to 12 hours, followed by at least a 12 hour plaster-free interval. Cover painful area once daily. Apply the plaster to intact, dry, non-irritated skin (after healing of the shingles). Remove hairs in affected area with scissors (do not shave). Remove the plaster from sachet and its surface liner before applying immediately to the skin. Plasters may be cut to size. Patients under 18 years: Not recommended. Contra-indications: Hypersensitivity to active substance, any excipients, or local anaesthetics of amide type (e.g. bupivacaine, etidocaine, mepivacaine and prilocaine). Warnings and precautions: Do not apply to inflamed or injured skin (e.g. active herpes zoster lesions, atopic dermatitis or wounds), mucous membranes or the eyes. Plasters contain propylene glycol which may cause skin irritation, methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions. Use with caution in patients with severe cardiac impairment, severe renal impairment or severe hepatic impairment. Interactions: No clinically relevant interactions have been observed in clinical studies. Absorption of lidocaine from the skin is low. Use with caution in patients receiving Class I antiarrhythmic drugs (e.g. tocainide, mexiletine) or other local anaesthetics. Pregnancy and lactation: Do not use during pregnancy or breast-feeding. Undesirable effects: Very common (greater than or equal to 10%): administration site reactions (e.g. erythema, rash, pruritus, burning). Uncommon (>0.1%-less than or equal to 1%): skin injury, skin lesion. Very rare (less than or equal to 0.01%) but potentially serious: anaphylaxis, hypersensitivity. Adverse reactions were predominantly of mild and moderate intensity. Systemic adverse reactions are unlikely. See SPC for full details. Overdose: Unlikely. If suspected, remove plasters, provide supportive treatment (see SPC). Legal classification: POM. Marketing Authorisation number, pack sizes and basic NHS cost: PL 21727/0016, 30 plasters (GBP 72.40). Marketing Authorisation Holder: Grunenthal Ltd, Regus Lakeside House, 1 Furzeground Way, Stockley Park East, Uxbridge, Middlesex, UB11 1BD, UK. Date of text: June 2008. V0138

Information about adverse event reporting can be found at:

Adverse events should also be reported to Grunenthal Ltd

(telephone +44(0)870-351-8960)


1) Scottish Medicines Consortium, NHS Scotland, website:

2) Cunningham, A. and Dworkin, R. (2000) The Management of

post-herpetic neuralgia. BMJ 321, 778-779

3) Shingles Support Society. Bowsher D. Treatment of post-herpetic

neuralgia in the elderly. Available at:

4) Herpes Viruses Association. Available at:

5) Versatis Summary of Product Characteristics

6) Baron R et al. Abstract presented at the Congress of the

European Federation of IASP Chapter, Istanbul 2006

7) Shingles Support Society. Bowsher D. Treatment of post-herpetic

neuralgia in the elderly. Available at:


For further information, please contact:

Janis Troup/Debra Lord at Right Angle Communications: Tel: +44(0)20-8846-3170 or or

Grunenthal medical information department: Tel: +44(0)870-351-8960 (follow options).

SOURCE Grunenthal Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
2. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
3. FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
4. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
5. Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities
6. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
8. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
9. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
10. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
11. Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, ... many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser ... used by a dentist in Gettysburg, PA . From routine visits to ...
(Date:11/24/2015)... ... , ... New patients who wish to seek treatment for missing teeth can ... her Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 ... Missing teeth can lead to a variety of complications if they are not replaced ...
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
Breaking Medicine News(10 mins):